International Journal of Geriatric Psychiatry · 2012 · 18 citations · 16 references
MedicineNeurologyNeuroscienceCognitive NeuroscienceDementiaNeuropsychiatryBehavioral SymptomsBrain ImagingDementia BiomarkersDementia TreatmentFrontotemporal DementiaNeuroimaging In Dementia18F-fluorodeoxyglucose Positron Emission TomographyCingulate Cortex FunctionFluorine-18 Fluorodeoxyglucose Positron Emission TomographyInsula LesionsMetabolic Activity DetectionMetabolic Activity ReductionSalience Network ConnectivitySemantic Dementia
OBJECTIVES: To follow up on the increases we reported in normalized metabolic activity in salience network hubs from a 2-month open-label study of memantine in frontotemporal dementia (FTD). METHODS: We repeated fluorodeoxyglucose positron emission tomography (FDG-PET) after 6 months of drug use and subjected the data to Statistical Parametrical Mapping (SPM) analysis to reveal clusters of significant change from baseline. We also sought correlations between changes in behavioral disturbances on the Frontal Behavioral Inventory (FBI) and the PET signal. RESULTS: Recruitment of one progressive nonfluent aphasia and one behavioral variant FTD precluded statistical analysis for any FTD subtype other than semantic dementia (SD). The baseline-to-6-month interval showed increased normalized metabolic activity in the left orbitofrontal cortex (p < 0.002) for five participants with SD. The 2-6-month interval revealed a late increase in normalized metabolic activity in the left insula (p < 0.013), right insula (p < 0.009), and left anterior cingulate (p < 0.005). The right anterior cingulate showed both an initial increase and a delayed further increase (2-6 months, p < 0.016). FBI scores worsened by 43.3%. One participant with SD opted not to continue memantine beyond 2 months yet showed similar FDG-PET increases. CONCLUSIONS: Increases in normalized cortical metabolic activity in salience network hubs were sustained in SD over a 6-month period. Because one participant without medication also showed these changes, further investigation is recommended through a double-blind, placebo-controlled study with FDG-PET as an outcome measure.
16
The Clinical Dementia Rating (CDR)
John C. Morris · Neurology · 1993 · 10K citations
Medicine, Neurology, Psychiatry +12
Memantine in Moderate-to-Severe Alzheimer's Disease
Barry Reisberg, Rachelle S. Doody, Albrecht Stöffler et al. · New England Journal of Medicine · 2003 · 2K citations · Full text
Medicine, Neuroscience, Pharmacology +16
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
David S. Knopman, Joel H. Kramer, Bradley F. Boeve et al. · Brain · 2008 · 450 citations · Full text